McLean A, Cardenas D D, Burgess D, Gamzu E
Neuro Care Inc., Seattle, Washington.
Brain Inj. 1991 Oct-Dec;5(4):375-80. doi: 10.3109/02699059109008110.
The current study evaluated under double-blind placebo-controlled conditions, the safety and efficacy of 400 mg pramiracetam sulphate TID in treating memory and other cognitive problems of males who have sustained brain injuries. The results of the study indicate that subject performance in measures of memory, especially delayed recall, evidenced clinically significant improvements after the administration of pramiracetam sulphate as compared to placebo. This improvement was maintained during an 18-month open-trial period on the medication as well as during a 1-month follow-up period after the pramiracetam was discontinued.
本研究在双盲安慰剂对照条件下，评估了每日三次服用400毫克硫酸普拉西坦治疗脑损伤男性记忆及其他认知问题的安全性和有效性。研究结果表明，与安慰剂相比，服用硫酸普拉西坦后，受试者在记忆测试（尤其是延迟回忆）中的表现有临床显著改善。在为期18个月的药物开放试验期以及停用硫酸普拉西坦后的1个月随访期内，这种改善一直保持。
